CLINICAL_TRIALS
trial_result
· 2015-06-18
Clinical Trial Update: Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Summary
Phase 2 trial for LBH589 in patients with low or intermediate-1 risk myelodysplastic syndrome was terminated; results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2015-06-18